2007-2008 CANCER COMMITTEE
MERCY HOSPITAL FAIRFIELD

Physician Members

Paula Weisenberger, MD, Chair - Medical Oncology
Holenarsipur Ramadas, MD, ACOS Liaison - General Surgery
Anthony Behler, MD - Internal Medicine
Susan Cha, MD - Radiology
William Cook, MD - Cardiothoracic Surgery
Edward Crane, MD - Medical Oncology
Douglas Hingsbergen, MD - General Surgery
Donald Imwalle, MD - Radiology
Edmond Rolfes, MD (2008) - Pathology
James Swinehart, MD (2007) - Pathology
James Wolfe, MD - Pathology
Bradford Woodall, MD - Radiology
Ralph Wright, MD - Radiation Oncology

Non-Physician Members

Marci Butts - Rehabilitative Services
Charla Carter, CTR - Cancer Registry
Deanne Dalhart, RPh - Pharmacy
Jane Fermann, RN - Quality Improvement
Patricia Davis-Hagens, RN - Administration
Michelle Haas, RN - Enterostomal Therapy
Anne Henry - American Cancer Society
Judy Kraft, RN, BSN - Quality Management
Cindy Muron, RN, BAN, MBA - Palliative Care Services
Nancy Murrin, RN, BSN, OCN - Oncology Nursing, Cancer Care
Ann Popoff, RD - Food and Nutrition Services
Reverend Lucy Vick, BA, MA - Spiritual Care Services
Vanessa Walker, LSW, MSW - Discharge Planning
2007 CANCER PROGRAM SUMMARY

Mercy Hospital Fairfield offers the highest quality of cancer care as evidenced by the “approval with commendation” status of our cancer program, received by the Commission on Cancer, American College of Surgeons in 2005. Our Cancer Program was also awarded the “Outstanding Achievement Award” for excellence in the key areas of patient care. Achieving this level of compliance with the required standards of care set by the CoC, assures our patients that they will receive the best of care from diagnosis, through the treatment period and continuing to end of life.

In addition to our wide range of diagnostic and treatment services, our hospital offers many programs to provide assistance to both our patients and their families as they cope with a diagnosis of cancer. Our support services include nutritional support, spiritual support, rehabilitation, palliative care, educational programs for our patients and the community, information on access to clinical trials and cancer support groups and programs, many of which are provided through participation with the American Cancer Society.

Our cancer program, under the leadership of our cancer committee, continues to strive for excellence by setting annual goals to improve and enhance our services and meet the needs of the area we serve.

The Mercy Fairfield Cancer Committee implemented many patient care improvements, sponsored many patient, community and staff educational offerings and improved many of our services last year. Among the 2007 Cancer Program Achievements are:

- Promoted genetic testing and education to primary care physicians to identify those at high risk for cancer gene susceptibility
- Provided Mobile PET Scanning at the facility for specific types of cancers, such as breast, cervical, colorectal, esophageal, head and neck, lung, lymphoma, melanoma and thyroid as well as other medical conditions
- Participated in American Cancer Society community awareness activities, cancer screening opportunities and corporate sponsorship of the Relay For Life
- Partnered with Rehabilitation Services to promote early intervention to promote energy conservation strategies
- Promoted cancer awareness, prevention, early detection, treatment and survivorship through participation in annual health fair, Relay For Life, mobile mammography and screening mammography offered at Women’s Center
The Cancer Registry is a vital component of the cancer program, providing data for programmatic and administrative planning, research, and for monitoring patient outcomes. Data are collected according to the current standards of the Commission on Cancer to create a detailed cancer–focused record for all reportable tumors diagnosed and/or treated at our hospital. Each record entered into the database contains information on the diagnosis, extent of disease, treatment received, recurrence of disease and lifetime follow-up for each patient. Aggregate data are analyzed and published without patient identifiers to protect the confidentiality of each patient entered into the cancer database according to Ohio state laws and HIPAA regulations.

A Cancer Registrar performs the collection, interpretation, analysis and reporting of cancer data. The National Cancer Registrars Association defines Cancer Registrars as data management experts who collect and report cancer statistics for various healthcare agencies. Registrars work closely with physicians, administrators, researchers, and health care planners to provide support for cancer program development, ensure compliance of reporting standards, and serve as a valuable resource for cancer information with the ultimate goal of preventing and controlling cancer. The cancer registrar is involved in managing and analyzing clinical cancer information for the purpose of education, research, and outcome measurement.

The cancer programs at Mercy Health Partners make accurate data collection a priority. The cancer registry at Mercy Fairfield is a community-based hospital registry, staffed by a Certified Tumor Registrar (CTR). Certification is maintained by continuing education in cancer data collection standards, cancer program requirements and in the diagnosis and treatment of cancer.

Registry data is submitted 100% error free to the National Cancer Data Base (NCDB) annually as a requirement of the Commission on Cancer for all approved cancer programs. Submission of data to the National Cancer Database provides feedback to assess the quality of patient care. This feedback enables cancer programs to compare treatment and outcomes with the regional, state and national patterns. Major differences between the facility data and the national data are reviewed in an effort to identify the reasons for these differences.

Cancer data is also submitted to the Ohio Cancer Incidence Surveillance System (OCISS). All reported data are used to support research, track trends, initiate epidemiologic studies, generate journal articles and provide data for allocation of services. The data are analyzed to identify opportunities for community cancer awareness and screening where higher stages (III-IV) of cancers are seen. This data also provides a means of identifying possible cancer clusters within the state.

Registry data are utilized at Cancer Conferences to facilitate discussion of treatment, AJCC stage, follow-up and survival of various cancers throughout the year.

**Cancer Conferences**

Mercy Hospital Fairfield offers prospective, patient-oriented and multidisciplinary Cancer Conferences, which provide free consultative services to our patients and education to the medical and hospital staff. Medical Oncology, Radiation Oncology, Diagnostic Radiology, Pathology and Surgery specialties are available at the conferences to discuss possible treatment options for the types of cancers presented at the conferences. Patient identities are kept confidential.

National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology, information on open clinical trials, and facility data are provided for the cancer sites presented.

Cancer Conferences are held at Mercy Hospital Fairfield on the second Thursday of each month at 7:30 a.m. in the Medical Staff Conference Room and are approved by the Ohio State Medical Association for one Category 1 CME credit hour. Physicians may contact the Cancer Registry (870-7839), the Medical Staff office (870-7078) for more information or to receive a current meeting schedule. Contact Pathology (870-7032) to schedule a patient to be presented at a Cancer Conference.
The total number of cases in the Fairfield Cancer Registry since the 1984 reference date is 5,910 cases. During 2007, 459 analytic cases were accessioned into the registry database, with an additional 22 non-analytic (recurrent cancer) cases accessioned into the database. The statistics contained in this report represent only analytic (newly diagnosed) cancer cases.

Site Distribution

<table>
<thead>
<tr>
<th>Site Distribution</th>
<th>Percent of Newly Diagnosed Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUNG/BRONCHUS</td>
<td>20%</td>
</tr>
<tr>
<td>COLON</td>
<td>17%</td>
</tr>
<tr>
<td>PROSTATE</td>
<td>12%</td>
</tr>
<tr>
<td>KIDNEY/RENAL</td>
<td>6%</td>
</tr>
<tr>
<td>BREAST</td>
<td>4%</td>
</tr>
<tr>
<td>BLADDER</td>
<td>4%</td>
</tr>
<tr>
<td>NON-HODGKINS</td>
<td>4%</td>
</tr>
<tr>
<td>UNKNOWN PRIMARY</td>
<td>4%</td>
</tr>
<tr>
<td>CORPUS UTERI</td>
<td>4%</td>
</tr>
<tr>
<td>OTHER DIGESTIVE SYSTEM</td>
<td>4%</td>
</tr>
<tr>
<td>OTHER CNS</td>
<td>3%</td>
</tr>
<tr>
<td>MELANOMA</td>
<td>2%</td>
</tr>
<tr>
<td>PANCREAS</td>
<td>2%</td>
</tr>
<tr>
<td>THYROID</td>
<td>1%</td>
</tr>
<tr>
<td>BRAIN, MALIGNANT</td>
<td>1%</td>
</tr>
<tr>
<td>HODGKINS DISEASE</td>
<td>1%</td>
</tr>
<tr>
<td>LEUKEMIA</td>
<td>1%</td>
</tr>
<tr>
<td>STOMACH</td>
<td>1%</td>
</tr>
<tr>
<td>OVARY</td>
<td>1%</td>
</tr>
<tr>
<td>CERVIX UTERI</td>
<td>1%</td>
</tr>
<tr>
<td>LEUKEMIA</td>
<td>1%</td>
</tr>
<tr>
<td>LARYNX</td>
<td>1%</td>
</tr>
<tr>
<td>MULTIPLE MYELOMA</td>
<td>1%</td>
</tr>
<tr>
<td>LIVER</td>
<td>1%</td>
</tr>
<tr>
<td>ANUS/ANAL CANAL</td>
<td>1%</td>
</tr>
</tbody>
</table>

Other sites with less than 1% include: esophagus, connective and soft tissue, testis, other skin, other urinary system, other oral cavity, other ill-defined, other female genital, blood & bone marrow, nasal sinus, bone, and other male genital.
**Top Cancer Sites In 2007**

The top sites in 2007 were lung (20 percent), colorectal (17 percent), prostate (12 percent), kidney/renal pelvis (6 percent), breast (5 percent), and bladder (4 percent). Compared with the estimated 2007 state and national data, our incidence of melanoma and breast cancer was lower. Our lower incidence of melanoma cases may be due to the fact that many excisions are performed in outpatient surgery centers. The lower incidence of breast cancer at our hospital may also be due to an increase in the number of surgical procedures, chemotherapy and radiation being performed in outpatient treatment centers. Our colorectal incidence is higher than both state and national incidence, which may be due to the elderly population in our service area.

**Gender Comparisons**

Distribution of our cases by gender revealed that 246 (54 percent) were males and 213 (46 percent) were females. The most frequent cancer sites in women were lung, colorectal, and breast. Lung, colorectal and prostate cancers were the most frequently seen cancers in our male patients. This closely reflects the national incidence by gender.

Compared with national data, we treated fewer patients with breast and prostate cancer. This is likely due to the fact that we do not perform radiation treatment at our facility and radiation is often given for these two types of cancer. Colorectal and lung cancer in both women and men is higher at our hospital than is seen nationally. This may be due to our elderly service area.
Melanoma Incidence and Mortality Trends

Incidence – Skin cancers account for at least half of all cancers but less than 5% of skin cancers are melanomas. Incidence rates increase with age, however, melanoma is not uncommon among those younger than 30 and is one of the more common cancers in adolescents and young adults. Males are slightly more likely (56%) than females and Caucasians are at least ten times more likely than African Americans to be diagnosed with melanoma. It is estimated that approximately 62,480 new cases of melanoma will be diagnosed in 2008, according to the American Cancer Society (ACS).

In the 1970’s, melanoma incidence began to rise about 6% per year, slowing to 3% per year in the 1980’s and 1990’s. Between 1995-2004, melanoma continued to steadily rise at about 1% per year. This is in sharp contrast to overall cancer rates that declined steadily by approximately 0.6% per year. During this same period, a 50% increase was seen in melanoma among young women (15-30) and in the 60 years and older age group. Increased rates have been attributed to the thinning of the ozone layer and more exposure to Ultraviolet (UV) radiation, an increase in leisure time and outdoor activities, and the popularity of tanning beds.

Mortality – Melanoma is the most serious skin cancer and is the cause of most skin cancer deaths. The ACS estimates that in 2008, about 8,420 people will die from melanoma. The death rate for those over 50 years of age stabilized in the 1990’s and is dropping for those under 50.

Melanoma Incidence Comparisons

2007 State Incidence Comparisons

Colorado, Connecticut, Idaho, and Utah lead the nation with melanoma incidence at 6%. Other states with a high incidence (5%) include Arizona, California, Hawaii, Kentucky, Maine, Massachusetts, New Hampshire, New Mexico, North Carolina, Oregon, Rhode Island, and Washington. Melanoma incidence in the state of Ohio is estimated at 4%.

The District of Columbia ranks lowest in our nation for melanoma incidence (2%).

National, Ohio and Hospital Incidence Comparisons

Nationally, it is estimated that melanoma will account for about 4% of the cancers diagnosed in 2007. This mirrors the incidence for Ohio and at our hospital.

Risk Factors

- Ultraviolet (UV) light exposure-UV radiation causes damage to genes in the skin cells. Sources include sunlight and tanning beds/booths.
- Gender—men are more at risk, likely due to more sun exposure (primarily occupational-related exposure)
- Moles—multiple or atypical
- Age—risk increases with age, but is common in younger people
- Race—whites are more than 10 times more at risk than blacks
- Family or personal history
- Fair complexion—natural blondes and red-heads and people with freckles have greater risk
- Xeroderma pigmentosum— a rare inherited condition, increases risk for all skin cancers
- Immune suppression
- Sunburns, especially severe childhood sunburns
**Prevention**

Most skin cancers, including melanoma, can be prevented by protecting your skin and limiting exposure to the sun. The ACS recommends:

- Limit or avoid ultraviolet exposure during the midday hours (10 am to 4 pm).
- When outdoors, protect your skin; use the “Slip, Slap, Slop” method:
  - Wear protective clothing (Slip)
  - Wear a hat (Slap)
  - Use sunscreen with a sun protection factor (SPF) of 15 or higher (Slop)
- Wear sunglasses
- Seek shade
- Protect children from severe sunburns
- Avoid tanning beds and sun lamps

**Screening and Early Detection**

The best way to detect skin cancer early is to recognize changes in skin growths or the appearance of new growths. Adults should examine their skin regularly. The American Cancer Society recommends thorough monthly self-examinations of your skin. Any areas of concern should be reported to your physician. It is important to closely watch moles since some may develop into melanoma. Ask your physician annually to examine areas you cannot see. If you have a personal or family history of melanoma, your physician should examine your skin about 2-3 times a year.

**Signs and Symptoms**

Important warning signs of melanoma include changes in size, shape or color of a skin lesion or the appearance of a new growth on the skin. Changes that occur over a few days are generally harmless but changes that progress over a month or more should be evaluated by your physician. Melanomas often start as small, mole-like growths that increase in size and change color.

A simple ABCD rule outlines the warning signals of the most common type of melanoma. A is for asymmetry (one half of the mole does not match the other half); B is for border irregularity (the edges are ragged, notched, or blurred); C is for color (the pigmentation is not uniform, with variable degrees of tan, brown or black); D is for diameter greater than 6 millimeters (about the size of a pencil eraser).

**Diagnostic Methods**

Usually, the first step is for your doctor to take your medical history and perform a physical exam. Many dermatologists use dermatoscopy, using a special magnifying lens with a light source to see the area more clearly. Often this test can determine that the lesion is non-cancerous.

If the lesion is suspicious for cancer, or melanoma, an incisional or excisional biopsy of the area is performed. An incisional biopsy removes only a small piece of the lesion. A shave biopsy or punch biopsy may be performed to obtain a sample of the lesion if melanoma risk is low. An excisional biopsy removes the entire lesion and is the preferred method to diagnose melanoma. If enlarged lymph nodes are found on physical exam, a fine needle aspiration or excisional biopsy may be done to determine whether the melanoma has spread. The preferred method to determine whether the melanoma has spread to the lymph nodes is sentinel lymph node mapping and biopsy. In this procedure, a dye is injected into the lymph nodes that drain the area where the melanoma originated. If the melanoma has spread, these lymph nodes are usually the first place it would go. If the node is negative for melanoma, no more lymph nodes are removed because it is likely the melanoma has not spread. If the sentinel node is positive for melanoma, more nodes will be taken for microscopic exam.

Imaging tests such as chest x-ray, Computed Tomography (CT scan), Magnetic resonance imaging (MRI), Positron emission tomography (PET) and bone scan are used to determine if the melanoma has spread to lymph nodes or other organs. Very early stage melanoma that is unlikely to have spread may not require these tests. Approximately 5% of melanomas present with metastatic disease but no identifiable primary lesion. The most common presentation for unknown primary melanoma is a lymph node mass. A few patients present with metastases to an internal organ without a known primary lesion. For this type of presentation, a complete work-up is needed to attempt to locate a primary site and to determine the extent of metastasis.
Examples of Benign and Malignant Moles

<table>
<thead>
<tr>
<th>Normal Mole</th>
<th>Melanoma</th>
<th>Sign</th>
<th>Characteristic</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Normal Mole" /></td>
<td><img src="image2.png" alt="Melanoma" /></td>
<td>Asymmetry</td>
<td>when half of the mole does not match the other half</td>
</tr>
<tr>
<td><img src="image3.png" alt="Normal Mole" /></td>
<td><img src="image4.png" alt="Melanoma" /></td>
<td>Border</td>
<td>when the border (edges) of the mole are ragged or irregular</td>
</tr>
<tr>
<td><img src="image5.png" alt="Normal Mole" /></td>
<td><img src="image6.png" alt="Melanoma" /></td>
<td>Color</td>
<td>when the color of the mole varies throughout</td>
</tr>
<tr>
<td><img src="image7.png" alt="Normal Mole" /></td>
<td><img src="image8.png" alt="Melanoma" /></td>
<td>Diameter</td>
<td>if the mole's diameter is larger than a pencil's eraser</td>
</tr>
</tbody>
</table>

*Photographs Used By Permission: National Cancer Institute*
2000-2005 DATA COMPARISON

Factors that Determine Treatment and Prognosis

Age – Age at diagnosis comparison to the national showed that we saw more patients over age 60, accounting for 22% of our melanoma cases and only 15% nationally. This can be attributed to our elderly service area. The percentages per gender were very similar. Nationally, 56% were male and 44% were female. At our hospital, 36% were male and 64% were female.

Tumor Characteristics

Several characteristics of primary melanoma tumors help predict the prognosis and risk of metastases.

- Tumor thickness (Breslow depth) is the strongest predictive characteristic for recurrence and is the most important factor in determining patient management. Tumor thickness is associated with poor prognosis, and forms the primary basis for tumor staging.
- Levels of invasion, based on the dermal layers of the skin, are known as Clark’s levels and are also associated with outcomes.

Clinical factors such as anatomic site, ulceration, and gender are also prognostic factors for survival.

- Extremity melanomas generally have a better prognosis than those on the head and neck or trunk. However, distal extremity lesions, (foot and hand) have prognoses similar to primaries of the trunk.
- Mucosal and mucocutaneous melanomas have an overall poor prognosis.
- Ulceration is a strong prognostic factor and is included in the AJCC staging system.
- Many studies have shown that melanoma survival rates for women are somewhat better than for men. The reasons for gender-related differences in survival are unknown.

Stage at diagnosis – Melanoma staging is based on tumor thickness (T), nodal involvement (N) and distant metastasis (M).
Histology Distribution

Comparison of our histologies to the United States showed that the more defined histologies are used more often than malignant melanoma NOS.

Treatment

Removal and microscopic examination of all suspicious skin lesions is essential. For malignant melanoma, the primary growth must be adequately excised. Depending on the extent of local growth, one or more nearby lymph nodes may be removed. Melanomas with deep invasion or that have spread to lymph nodes may be treated with immunotherapy or radiation therapy. Advanced cases of melanoma are treated with palliative surgery, immunotherapy, and/or chemotherapy.

Surgery – The primary treatment for melanoma is surgery and is usually considered to be curative for early stage melanomas. Several types of surgery are used, depending on tumor thickness and location of tumor on the body. Adequate surgical margins (the normal, healthy skin around the edges of the tumor) are considered necessary for a good prognosis.

- Simple excision - can be used as a cure for thin melanomas
- Re-excision after biopsy - provides adequate margins for thicker lesions (see table below)
- Mohs surgery - may be used when smaller margins are needed to avoid disfigurement, for example, facial lesions
- Amputation - used only for deep melanomas involving a finger or toe

Recommended Surgical Margins
Margin size is based on tumor thickness. Thicker lesions require deeper margins.

<table>
<thead>
<tr>
<th>Tumor thickness</th>
<th>Recommended margins</th>
</tr>
</thead>
<tbody>
<tr>
<td>In situ</td>
<td>0.5 cm</td>
</tr>
<tr>
<td>Less than 1 mm</td>
<td>1 cm</td>
</tr>
<tr>
<td>1 to 2 mm</td>
<td>1 to 2 cm</td>
</tr>
<tr>
<td>2 to 4 mm</td>
<td>2 cm</td>
</tr>
<tr>
<td>Over 4 mm</td>
<td>At least 2 cm</td>
</tr>
</tbody>
</table>
ADJUVANT THERAPIES

Chemotherapy

Although chemotherapy is usually not as effective in melanoma as in some other types of cancer, it may relieve symptoms or extend survival for some patients. There are several types of chemotherapy available to treat advanced melanoma.

- Dacarbazine may be used alone or in combination with other chemotherapy drugs such as carmustine and cisplatin. These 3 drugs combined with tamoxifen (a hormonal therapy drug) is called the “Dartmouth regimen.”
- Paclitaxel alone or in combination with cisplatin or carboplatin
- Temodar, which can be given in a pill, either by itself or combined with interferon
- Cisplatin, vinblastine and dacarbazine in combination (called the “CVD regimen”)

Immunotherapy

Immunotherapy works by enhancing and encouraging the body’s immune system to more effectively recognize and destroy cancer cells. Cytokines are naturally produced proteins that boost the immune system in a general way. Two man-made versions of cytokines, interferon-alpha and interleukin-2, can be used to treat advanced melanoma (stage 3 and 4).

- Biochemotherapy or chemoimmunotherapy
  Interferon-alpha and interleukin-2 can also be combined with chemotherapy to treat stage 4 melanoma. Combining chemotherapy drugs with 1 or more immunotherapy drug may be more effective than a single chemotherapy drug alone, but may not improve survival.

- Melanoma vaccines
  Melanoma vaccines are directed specifically at melanoma cells and are experimental, unproven therapies. Unlike vaccines that are meant to prevent infections, these vaccines are meant to treat an existing disease. In an attempt to stimulate the body's immune system to destroy other melanoma cells in the body, killed melanoma cells or parts of cells (called antigens) can be injected into a patient as a vaccine. Usually, the cells or antigens are mixed with other substances that help stimulate the body’s immune system as a whole.

- Bacille Calmette-Guerin (BCG) vaccine
  BCG, working like a cytokine, can be used to stimulate the entire immune system. Sometimes BCG is injected directly into tumors as treatment for stage 3 melanomas.

- Imiquimod cream
  Imiquimod cream stimulates a local immune response and may be suitable treatment for very early stage melanomas (stage 0) of the face, when surgery might cause disfigurement. However, there is some disagreement among physicians over using this cream for melanomas.

Radiation

Radiation is usually not used to treat the primary tumor. However, it can be used as adjuvant therapy to treat lymph node areas, especially if nodal metastasis is present or to treat distant metastatic sites. Patients with recurrent melanoma may receive radiation to the primary skin area. The primary role of radiation therapy for melanoma is to provide palliation (relief from symptoms) to metastatic areas, such as the brain or bone.
OTHER TREATMENT TYPES

Palliative Treatment

When melanoma is diagnosed in late stage the focus of treatment may be palliative. Palliative treatment can include surgery, chemotherapy, radiation, immunotherapy, a combination of these, or simply consist of comfort measures alone. Comfort measures may also be appropriate for patients who are not candidates for treatment due to age, comorbidity and high-risk. The Palliative Care programs at Mercy Health Partners provide a wide range of services to our patients that cover the spectrum of physical, emotional, and practical needs.

Clinical Trials

Clinical trials for cancer treatment offer additional treatment options, including new drugs, new surgery or radiation therapy techniques, or even complementary or alternative medicines. Some trials study drugs that are already approved for one type of cancer to see if it works on a different type of cancer or works better when given a certain way or when combined with other treatments. Clinical trials provide access to treatment that is not otherwise available, and might be safer or more effective than current treatment options. When clinical trials show that a new treatment is better than the current treatment, the new treatment may become a standard treatment. All clinical trials are reviewed and approved by scientific panels to make sure they are ethical, safe, and at least as good as, and possibly better than, the standard and currently available treatments.

According to the American Cancer Society, the number one reason people give for not taking part in a clinical trial is that they didn’t know the studies were an option for them. Before starting treatment, patients may want to think about taking part in a clinical trial. Ideally, the patient, family, and health care team should be involved in the decision on choosing the most appropriate cancer treatment.

Treatment Comparison to National Cancer Database

At Mercy Hospital Fairfield, 90% of the cutaneous melanomas were surgically resected. We had four (4) stage 0 cases and all were treated with surgery only, compared to 96% in the U.S. We had fifteen (15) stage 1 patients and 100% were treated with surgery only, compared to 97% nationally. Treatment for these stages was appropriate and is comparable to the U.S.

We had eight (8) stage 2 patients and 100% were treated with surgery only, compared to 91% nationally. More of our patients had surgery only, but this disparity is likely the result of our having only eight cases in the study group.

We had five (5) stage 3 cases. Four (4) patients received surgery only which was 80%, compared to 59% nationally. Again the small number in the group could skew the data. Another patient had surgery and immunotherapy which was 20% of the cases in the study group and this was similar to the national data.

There were only two (2) stage 4 cases. One (1) was treated with surgery and radiation therapy, while the other was treated with other therapy. Nationally, 50% of the patients were treated with other therapy.

Of our three (3) patients with unknown stage, 67% received surgery only (82% nationally). One patient received no therapy (33%) compared to 10% nationally. The percentage difference is probably because of the small numbers, again in the study group. The other national averages include surgery and immunotherapy (1% nationally), 6% other specified treatment, and 10% had no treatment.
<table>
<thead>
<tr>
<th>Treatment Type</th>
<th>Stage at Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stage 0</td>
</tr>
<tr>
<td>Surgery Only</td>
<td>96%</td>
</tr>
<tr>
<td>Radiation Only</td>
<td>0%</td>
</tr>
<tr>
<td>Surgery and Radiation</td>
<td>0%</td>
</tr>
<tr>
<td>Surgery and Chemotherapy</td>
<td>0%</td>
</tr>
<tr>
<td>Chemotherapy Only</td>
<td>0%</td>
</tr>
<tr>
<td>Surgery, Radiation and Chemotherapy</td>
<td>0%</td>
</tr>
<tr>
<td>Surgery and BRM</td>
<td>0%</td>
</tr>
<tr>
<td>Surgery, Chemotherapy and BRM</td>
<td>0%</td>
</tr>
<tr>
<td>Other Specified Therapy</td>
<td>0.3%</td>
</tr>
<tr>
<td>No 1st Course Rx</td>
<td>3%</td>
</tr>
<tr>
<td>% of Cases for Stage Group</td>
<td>23%</td>
</tr>
</tbody>
</table>

Source: National Cancer Database
Melanoma Survival by Stage

Melanoma accounts for 4% of skin cancers but causes 80% of skin cancer deaths. It has been shown that tumor thickness, age, ulceration, gender, anatomical site, and period of primary diagnosis can help to predict a patient’s overall survival. Deaths have continued to decline and this is attributed largely to early detection and treatment which are pivotal to melanoma survival. National data has shown that the five-year survival rate for melanoma has increased from 60% in the 1960s to 87% today. The five-year survival for regional disease which is when melanoma has spread to lymph nodes is 81%. The survival rate for distant disease is 12%.

Comparison of Mercy Hospital Fairfield to National Survival

Comparison of survival data for our patients diagnosed in 1998 through 2000 shows that for all stages our 5-year survival rates are comparable to the national rates.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="Survival Rate Table" /></td>
<td><img src="image" alt="Survival Rate Table" /></td>
</tr>
</tbody>
</table>
Summary of Findings:

The analysis of our experience with melanoma revealed the following:

• Incidence: Melanoma incidence has been increasing nationally at about 1% per year. Our percentage of 2007 melanoma cases was 4%, more than 1% higher than our percentage in 2006. Our increasing incidence trend reflects the national trend.

• Prognosis: Our stage at diagnosis is similar to the U.S. 79% of our patients were diagnosed at localized stages. However, 10% were diagnosed at later stages.

• Treatment: In looking at our treatment, we found that for all stages, our patients were treated appropriately and met current NCCN treatment guidelines. Our treatment was also comparable to the nation, given our small numbers and elderly patient group.

• Survival: Our 5-year survival for patients diagnosed in 1998-2000 was dissimilar to national. In reviewing the ages at diagnosis and treatment for these cases, it was found that the patients were treated appropriately for the stage group. It was determined that the survival differences are due to our very small numbers.

Recommendations:

• Increase prevention and early detection efforts
• Increase awareness of clinical trials

Community Outreach

The Mercy Hospital Fairfield Cancer Program, led by our Cancer Committee, is committed to making a difference in our community. We do this through several means, including promoting skin cancer awareness through participation in local Health Fairs, conducting Skin Cancer Awareness Month activities, increasing awareness of clinical trials and participation in or referral to American Cancer Society programs.

American Cancer Society Programs and Screening Guidelines

For information on American Cancer Society Programs and Screening Guidelines:
• Visit http://www.cancer.org or call 1-800-ACS-2345 (1-800-227-234)

Clinical Trial Information

For information on access to clinical trials in your area:

• Call the American Cancer Society, Clinical Trials Matching Service (a free, confidential program) at 1-800-303-5691 or visit www.cancer.org
• Visit the National Cancer Institute (NCI) website at: www.cancer.gov/clinicaltrials/search
• Visit the Coalition of Cancer Cooperative Groups at: www.cancertrialshelp.org